Page last updated: 2024-12-08
soyasaponin ii
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
soyasaponin II: isolated from the soybean Glycine max; RN given for (3beta,4beta,22beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Glycine | genus | A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.[MeSH] | Fabaceae | The large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH] |
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 443614 |
| CHEBI ID | 29679 |
| SCHEMBL ID | 14693925 |
| MeSH ID | M0276632 |
Synonyms (12)
| Synonym |
|---|
| 55319-36-3 |
| C12081 , |
| soyasaponin ii |
| CHEBI:29679 |
| SCHEMBL14693925 |
| (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8ar,9s,12ar,14as,14br)-9-hydro xy-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8 ,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-5-[(2s,3r,4s,5s)-4,5 -dihydroxy-3-[(2s,3r,4r,5s,6s)-3,4,5-trihy |
| Q27110224 |
| HY-122920 |
| E88950 |
| DTXSID801317250 |
| CS-0090443 |
| AKOS040760720 |
Research Excerpts
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| triterpenoid saponin | A terpene glycoside in which the terpene moiety is a triterpenoid. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 8 (88.89) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 19.99
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.99) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||